The CYP2C:TG haplotype was not significantly associated with CYP2C19-mediated omeprazole metabolism in admixed Latin American populations, not supporting its clinical implementation.
Observational
Yes
Is the CYP2C:TG haplotype associated with CYP2C19-mediated omeprazole metabolism in admixed Latin American populations?
The study does not support clinical implementation of CYP2C:TG haplotype testing for predicting CYP2C19 activity in admixed Latin American populations.
In these admixed Latin American populations, the CYP2C:TG haplotype was not significantly associated with CYP2C19-mediated omeprazole metabolism. This finding does not support clinical implementation of CYP2C:TG haplotype testing for predicting CYP2C19 activity and underscores the need for further research on this haplotype and its potential role in CYP2C19 metabolism across diverse populations in the context of pharmacogenetics.
Cruz et al. (Wed,) conducted a observational in CYP2C19-mediated omeprazole metabolism. CYP2C:TG haplotype was evaluated on CYP2C19-mediated omeprazole metabolism. The CYP2C:TG haplotype was not significantly associated with CYP2C19-mediated omeprazole metabolism in admixed Latin American populations, not supporting its clinical implementation.